{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-000046","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.568122+00:00","generated_at":"2026-06-20T15:55:06.453088+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis","bullets":["All 13 subjects tolerated LP-10 without product-related serious adverse events.","Dose response observed: decreased hematuria, cystoscopic bleeding/ulceration, improved urinary symptoms.","Responder analysis: complete response in 3 subjects, partial in 7, no response in 3 subjects.","LP-10 has Orphan Drug Designation; no FDA-approved treatment exists for hemorrhagic cystitis.","CEO to present results at Biotech Showcase 2023 on January 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-000046","json":"https://secwatch.observer/filing/0001753926-23-000046.json","markdown":"https://secwatch.observer/filing/0001753926-23-000046.md","text":"https://secwatch.observer/filing/0001753926-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/0001753926-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/g083352_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T15:55:06.453088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}